Skip to Main Content
Important information:
Important Information Regarding Medicare Advantage Plans – Learn More.
  • Sylvester Comprehensive Cancer Center |
  • Bascom Palmer Eye Institute
University of Miami Health
  • Appointments
  • Pay a Bill
  • Refer a Patient
  • International Patients
  • Donate Now
  • Search
  • Patient Login
  • Find a Doctor
  • Treatments Page 1
    Featured Treatments For
    • Allergy and Immunology
    • Arthritis (Rheumatology)
    • Bariatrics (Weight Loss Surgery)
    • Cancer (Oncology)
    • Cardiac and Vascular
    • Concierge Medicine
    • Dentistry
    • Dermatology
    • Diabetes
    • Ear, Nose, and Throat (ENT)
    • Emergency Care
    • Endocrinology, Diabetes and Metabolism
    • Executive Physicals
    • Eye Care (Ophthalmology)
    • Fertility Center
    • Gastrointestinal
    • Genetics
    • Geriatrics
    • Hepatology
    • High Blood Pressure (Hypertension)
    • Hyperbaric Oxygen Therapy
    • Infectious Diseases
    • Internal Medicine
    • Interventional Radiology
    • Lymphedema
    • Nephrology
    • Neurology
    • Neurosurgery
    • Obstetrics and Gynecology
    • Orthopaedics
    • Pain Management and Palliative Care
    • Pediatrics
    • Physical Medicine and Rehabilitation
    • Plastic Surgery
    • Primary Care
    • Psychiatry
    • Pulmonary Medicine
    • Radiology
    • Sleep Medicine
    • Sports Medicine Institute
    • Surgery
    • Transplant
    • UHealth Comprehensive Women’s Health Alliance
    • UHealth Premier
    • Urology
    View all Treatments
    Browse A-Z A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
    Featured Treatments For
    • Allergy and Immunology
    • Arthritis (Rheumatology)
    • Bariatrics (Weight Loss Surgery)
    • Cancer (Oncology)
    • Cardiac and Vascular
    • Concierge Medicine
    • Dentistry
    • Dermatology
    • Diabetes
    • Ear, Nose, and Throat (ENT)
    • Emergency Care
    • Endocrinology, Diabetes and Metabolism
    • Executive Physicals
    • Eye Care (Ophthalmology)
    • Fertility Center
    • Gastrointestinal
    • Genetics
    • Geriatrics
    • Hepatology
    • High Blood Pressure (Hypertension)
    • Hyperbaric Oxygen Therapy
    • Infectious Diseases
    • Internal Medicine
    • Interventional Radiology
    • Lymphedema
    • Nephrology
    • Neurology
    • Neurosurgery
    • Obstetrics and Gynecology
    • Orthopaedics
    • Pain Management and Palliative Care
    • Pediatrics
    • Physical Medicine and Rehabilitation
    • Plastic Surgery
    • Primary Care
    • Psychiatry
    • Pulmonary Medicine
    • Radiology
    • Sleep Medicine
    • Sports Medicine Institute
    • Surgery
    • Transplant
    • UHealth Comprehensive Women’s Health Alliance
    • UHealth Premier
    • Urology
    View all Treatments
  • Locations
  • Patients & Families
    Quick links
    • Appointments
    • Pay a Bill
    • Make a Gift
    • Insurance Plans Accepted
    • MyUHealthChart
    • Advance Directives
    For Patients & Families
    • Your First Visit
    • Medical Records
    • Frequently Asked Questions
    • Patient and Caregiver Resources
    • Patients & Families
    • Public Transportation
    • UHealth Clinic at Walgreens
    • Classes & Events
    • Support Groups
    • Interpreter Services
    • International Patients
    • UMiami Health Talks
    About Uhealth
    • Why Choose UHealth
    • Benefits of an Academic Medical Center
    • Mission & Values
    • Leadership
    • Community Health Improvement
    • Nursing at UHealth
    • Health News
    • Miller School of Medicine
    • University of Miami
    • Careers
    • Volunteers
    • Contact Us
    Clinical Trials
    • Find a Clinical Trial
    • Understanding Clinical Trials
    • Clinical Trials FAQ's
    Traveling from overseas?
    We can help plan your visit. Learn More
    Quick links
    • Appointments
    • Pay a Bill
    • Make a Gift
    • Insurance Plans Accepted
    • MyUHealthChart
    • Advance Directives
    For Patients & Families
    • Your First Visit
    • Medical Records
    • Frequently Asked Questions
    • Patient and Caregiver Resources
    • Patients & Families
    • Public Transportation
    • UHealth Clinic at Walgreens
    • Classes & Events
    • Support Groups
    • Interpreter Services
    • International Patients
    • UMiami Health Talks
    About Uhealth
    • Why Choose UHealth
    • Benefits of an Academic Medical Center
    • Mission & Values
    • Leadership
    • Community Health Improvement
    • Nursing at UHealth
    • Health News
    • Miller School of Medicine
    • University of Miami
    • Careers
    • Volunteers
    • Contact Us
    Clinical Trials
    • Find a Clinical Trial
    • Understanding Clinical Trials
    • Clinical Trials FAQ's
Patient Login
  • University of Miami Health System
  • Clinical Trials
  • Ph I Study in Adult Patients With Relapsed or Refractory Multiple Myeloma

Ph I Study in Adult Patients With Relapsed or Refractory Multiple Myeloma

Principal Investigator

Carl Landgren

Enrollment Status

Closed

Clinical Trial ID

Institutional Protocol # 20210897
National Clinical Trials Identifier NCT05027594

Clinical Trial Summary

This is a Phase I, first-in-human (FIH), open-label, non-randomized, multi-center study to
explore the safety, tolerability, pharmacokinetics and preliminary antitumor activity of
NMS-03597812 in adult patients with RRMM who have exhausted standard treatment options that
are expected to provide meaningful clinical benefit or for whom standard therapy is
considered unsuitable.


Phase

Phase 1


Funding Agency/Sponsor

Industrial


Disease

Myeloma


Enrollment Eligibility

Inclusion Criteria:
1. Patients must have a confirmed diagnosis of relapsed or relapsed and refractory
multiple myeloma (as per IMWG criteria)
2. Patients must have exhausted available therapeutic options that are expected to
provide meaningful clinical benefit, either through disease relapse, treatment
refractory disease, intolerance or refusal of the therapy.
3. Patients must have received at least three prior lines of therapy as defined by IMWG,
including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38
antibody.
4. Patients must have progressive/refractory disease to the last line of therapy.
5. Patients must have measurable disease, defined as any of the following:serum
monoclonal protein ≥ 0.5 g/dL by protein electrophoresis, ≥200 mg of monoclonal
protein in urine on 24-h electrophoresis, or serum immunoglobulin free light chain ≥10
mg/dL with abnormal free-light-chain ratio.
6. Adult (age ≥18 years) patients.
7. Karnofsky performance status ≥60%.
8. All acute toxic effects (excluding alopecia) of any prior therapy must have resolved
to NCI CTCAE version 5.0 Grade ≤1 or according to inclusion criterion 9.
9. Adequate hematological profile, renal, hepatic and pancreatic functions
10. All female patients with reproductive potential must have a negative pregnancy test
(serum or urine) within the screening period prior to start of the study drug.
11. Patients must use effective contraception or abstinence. Female patients of
childbearing potential must agree to use effective contraception or abstinence during
the period of therapy and in the following 90 days after discontinuation of study
treatment. Male patients must be surgically sterile or must agree to use effective
contraception or abstinence during the period of therapy and in the following 90 days
after discontinuation of study treatment.
12. Ability to swallow capsules intact (without chewing, crushing, or opening).
13. Willingness and ability to comply with scheduled visits, treatment plan, laboratory
tests and other study indications or procedures.
14. Signed and dated IRB/EC-approved Informed Consent
Exclusion Criteria:
1. Current enrollment in another interventional clinical study.
2. Diagnosis of primary refractory multiple myeloma defined as disease that is
non-responsive in patients who have never achieved a minimal response or better with
any therapy
3. Diagnosis of plasma cell leukemia, Waldenstrom's macroglobulinemia or amyloidosis.
4. Diagnosis of non-secretory myeloma.
5. Known central nervous system (CNS) involvement by multiple myeloma.
6. Known history of polyneuropathy, organomegaly, endocrinopathy, monoclonal protein and
skin changes (POEMS) syndrome.
7. Currently active second malignancy, except for adequately treated basal or squamous
cell skin cancer and/or conebiopsied in situ carcinoma of the cervix uteri and/or
superficial bladder cancer.
8. Autologous stem cell transplant ≤3 months prior to starting NMS-03597812.
9. Prior allogeneic hematopoietic stem cell transplant (HSCT) with either standard or
reduced intensity conditioning ≤6 months prior to starting NMS-03597812.
10. Active acute or chronic graft versus host disease (GVHD) requiring immunosuppressive
treatment. Patients who experienced GVHD requiring immunosuppressive treatment, must
have stopped immunosuppressive treatment >3 months prior to starting NMS-03597812.
11. Any anticancer agent within 3 weeks (6 weeks for immunotherapy or nitrosoureas).
12. Prior CAR-T cell <3 months prior to starting NMS-03597812.
13. Concomitant oral prednisone(or equivalent)>10 mg/day. Doses of corticosteroid must
have been stable for at least 7 days before startingNMS-03597812.
14. Major surgery within 4 weeks before treatment start.
15. Radiotherapy within 3 weeks prior to starting NMS-03597812. However, if the radiation
portal covered ≤ 5% of the bone marrow reserve, the patient may be enrolled
irrespective of the end date of radiotherapy.
16. Patient with evidence of clinically significant mucosal or internal bleeding.
17. Patient platelet transfusion refractory.
18. History of pancreatitis or current alcohol abuse.
19. Uncontrolled diabetes.
20. Patients with QTc interval ≥ 480 milliseconds or with risk factors for torsade de
pointes (e.g., uncontrolled heart failure, uncontrolled hypokalemia, history of
prolonged QTc interval or family history of long QT syndrome). For patients receiving
treatment with concomitant medications known to prolong the QTc interval, replacement
with another treatment should be considered. If replacement or discontinuation is not
clinically feasible, a careful risk/benefit evaluation should be performed prior to
enrollment.
21. Breast-feeding or planning to breast feed during the study or within 3 months after
study treatment.
22. Known hypersensitivity to any of the components of the NMS-03597812 drug product.
23. Known hypersensitivity to steroids or any of the components of the dexamethasone drug
product (applies only to the expansion cohort testing NMS-03597812 in combination with
dexamethasone).
24. Any of the following in the previous 6 months: myocardial infarction, unstable angina,
coronary/peripheral artery bypass graft, NYHA class III or IV congestive heart
failure, cerebrovascular accident or transient ischemic attack, or pulmonary embolism.
25. Uncontrolled bacterial, viral, or fungal infections including: known infection with
HIV, HBV and/or HCV; patients who are seropositive following HBV vaccine are eligible.
26. Known active gastrointestinal disease (e.g., documented gastrointestinal ulcer,
Crohn's disease, ulcerative colitis or short gut syndrome) or other malabsorption
syndromes that would impact drug absorption or represent a contra-indication for the
treatment with dexamethasone (NMS-03597812 and dexamethasone expansion cohort).
27. Other severe acute or chronic medical or psychiatric condition or laboratory
abnormality that may increase the risk associated with study participation or study
drug administration or may interfere with the interpretation of study results and, in
the judgment of the Investigator, would make the patient inappropriate for entry into
this study or could compromise protocol objectives in the opinion of the Investigator
and/or the Sponsor.
28. Patient who are receiving concomitant medications that are strong inducers or
inhibitors of CYP34A and CYP2C9 that cannot be replaced with alternative therapy.
29. Patients who are receiving concomitant medications that are sensitive substrates of
CYP3A4 and CYP2D6 with narrow therapeutic window that cannot be replaced with
alternative therapy.


Contact Information

Phone Number 305-243-2647
Get detailed information on ClinicalTrials.Gov

logo
alt="Twitter Logo">
USNWR Best Hospitals 2026-2027 USNWR Best Regional Hospitals 2026-2027
Quick links
  • Appointments
  • Find a Doctor
  • Pay a Bill
  • Insurance Plans Accepted
  • MyUHealthChart
  • Make a Gift
Patient & Families
  • Frequently Asked Questions
  • Medical Records
  • Interpreter Services
  • Clinical Trials
  • International Patients
  • UHealth Clinic at Walgreens
  • Support Groups
  • Price Transparency
  • Florida Health Finder
Healthcare Professionals
  • Refer a Patient
  • Physician & Executive Recruitment
  • Advanced Practice Providers
  • Immunology & Histocompatibility Laboratory
  • Nursing
  • Sleep Center
  • Sports Medicine Institute
  • Pathology Reference Services
About Uhealth
  • Why Choose UHealth
  • Benefits of an Academic Medical Center
  • Mission & Values
  • Leadership
  • Facts & Figures
  • Community Health Improvement
  • For Media
  • Miller School of Medicine
  • University of Miami
  • Careers
  • Volunteers
  • Supply Chain
  • Contact Us

Medical Disclaimer | Terms of Use | Privacy Statement | HIPAA Notice of Privacy Practices | Non-Discrimination Policy | No Surprises Billing Rights
© 2026 University of Miami Health System. All rights reserved.